



KEI Industries Limited

Registered and Corporate Office: D-90, Okhla Industrial Area, Phase-1, New Delhi- 110020 **CIN:** L74899DL1992PLC051527
Tel.: +91-11-26818840/8642/0242, Email: info@kei-ind.com Website: www.kei-ind.com

KEI/BSE/2025-26

Date: 24.09.2025

**The Manager,
Listing Operation,
BSE Limited,
25th Floor, Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai- 400 001**

Sub: Intimation of newspaper publication – Special Window for Re-lodgement of Transfer Requests of Physical Shares

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of the advertisement published in the following newspapers on September 24, 2025, regarding the public notice for the opening of the Special Window for re-lodgement of transfer requests of physical shares:

1. Financial Express (All edition) in English Language on 24.09.2025.
2. Jansatta (Delhi edition) in Hindi Language on 24.09.2025.

This is for the information of the exchange and the members.

**Yours truly,
For KEI INDUSTRIES LIMITED**

**(KISHORE KUNAL)
Sr.VP (Corporate Finance) & Company Secretary**

CC:

**The National Stock Exchange of India Ltd.
Listing Division, Exchange Plaza, Plot No. C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051**

**The Calcutta Stock Exchange Ltd.
The Senior Manager, Listing Division,
7, Lyons Range, Kolkata-700001**



Continued from previous page...

6) Allocation to Market Maker: The Basis of Allotment to Market Maker who have bid at Issue Price of ₹ 120.00/- per Equity Shares or above, was finalized in consultation with BSE. The category was subscribed by 1 time i.e. for 1,68,000 Equity shares. The total number of shares allotted in this category is 1,68,000 Equity Shares. The category wise details of the Basis of Allotment are as under:

No. of Shares Applied for (Category wise)	No. of applications received	% of Total	Total No. of Equity Shares applied in this Category	% of Total	No. of Equity Shares allocated/ allotted per Applicant	Ratio	Total Number of shares allotted	Surplus/ Deficit
1,68,000	1	100	1,68,000	100	1,68,000	1	1,68,000	0

The Board of Directors of the Company at its meeting held on September 22, 2025 has approved the Basis of Allocation of Equity Shares as approved by the Designated Stock Exchange viz. BSE and has authorized the corporate action for issue of the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBs have been dispatched mailed for unlocking of funds and transfer to the public Issue Account on or before September 22, 2025. In case the same is not received within ten days, Investors may contact the registrar to the issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on September 23, 2025 for credit in to the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the Listing and Trading approval from BSE and the trading of Equity shares is expected to commence on or before September 24, 2025.

Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the prospectus dated September 19, 2025 filed with the Registrar of companies, Ahmedabad Gujarat ("RoC").

INVESTORS, PLEASE NOTE

The details of the allotment made would also be hosted on the website of the Registrar to the issue, **Cameo Corporate Services Limited** at investor@cameoindia.com. All future correspondence in this regard may kindly be addressed to the Registrar to the issue quoting full name of the First/ Sole Bidder Serial number of the ASBA form, number of Equity Shares bid for, Bidder DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and copy of the Acknowledgment Slip received from the Designated Intermediary and payment details at the address given below:

Cameo Corporate Services Limited

Address: Subramaniam Building, No. 1, Club House Road, Chennai - 600002, India

Telephone: 044 4002 0700

E-mail: ipo@cameoindia.com

Investor Grievance E-mail: investor@cameoindia.com

Website: www.cameoindia.com

Contact Person: Ms. K Sreepriya

SEBI registration number: INR000003753

On behalf of Board of Directors
For, Sampat Aluminium Limited

Sd/-

Sanket Sanjay Deora

Chairman & Managing Director

DIN: 01417446

Place: Gujarat

Date: September 23, 2025

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF SAMPAT ALUMINIUM LIMITED.

Disclaimer: Sampat Aluminium Limited is proposing, subject to market conditions, public issue of its equity shares and had filed the Prospectus with the Registrar of Companies, Ahmedabad, Gujarat. The Prospectus is available on the website of the Book Running Lead Manager at ib.marwadichandaranagroup.com, website of the BSE i.e., www.bseindia.com and website of Issuer Company at www.sampataluminium.com. Investors should note that investment in Equity Shares involves a high degree of risk. For details, investors shall refer to and rely on the Prospectus including the section titled "Risk Factors" beginning on page 26 of the Prospectus, which has been filed with ROC. The Equity Shares have not been and will not be registered under the US Securities Act (the "Securities Act") or any state securities law in United States and may not be issued or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in the Regulation S under the Securities Act), except pursuant to an exemption from, or in a transaction not subject to the registration requirements of the Securities Act of 1933.

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA



Scan this QR to view the RHP

TELGE PROJECTS LIMITED

CIN: U29256PN2018PLC174381

Our Company was originally incorporated under the name "Telge Projects Private Limited" under the provisions of the Companies Act, 2013 vide Certificate of Incorporation dated January 16, 2018, issued by the Registrar of Companies, Central Registration Centre. Subsequently the status of the Company was changed to public limited and the name of our Company was changed to "Telge Projects Limited" vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting of our Company held on December 18, 2023. The fresh certificate of incorporation consequent to conversion was issued on January 02, 2024, by Registrar of Companies, ROC Pune. The Corporate Identification Number of our Company is U29256PN2018PLC174381.

Registered Office: Unit No. 502A, 5th floor, Om Chambers, Plot No. T-29, 30, 31, T Block, Bhosari I.E., Pune, Pune City, Maharashtra, India- 411026

Telephone: +91 7757950799 | **Email:** compliance@telgeprojects.com | **Website:** <https://telgeprojects.com>

Contact Person: Ms. Barkha Mohit Bharuka, Company Secretary and Compliance Officer | **CIN:** U29256PN2018PLC174381

THE PROMOTER OF OUR COMPANY IS MS. SHRADDHA SHAILESH TELGE

"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE (BSE SME)."

THE ISSUE

INITIAL PUBLIC OFFER OF UPTO 25,94,400 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH (THE "EQUITY SHARES") OF TELGE PROJECTS LIMITED ("OUR COMPANY" OR "TELGE PROJECTS" OR "THE ISSUER") FOR CASH AT A PRICE OF ₹ [●] PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [●] PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ [●] LAKHS (THE "ISSUE"), OF WHICH UPTO 1,30,800 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ [●] PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [●] PER EQUITY SHARE AGGREGATING TO ₹ [●] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E., NET ISSUE OF UPTO 24,63,600 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ [●] PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [●] PER EQUITY SHARE AGGREGATING TO ₹ [●] LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.50 % AND 25.16 % RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

CORRIGENDUM: NOTICE TO INVESTORS

This is with reference to the Red Herring Prospectus dated September 16, 2025 filed with the Registrar of Companies (ROC), Pune on September 16, 2025

The attention of investors is drawn to the following:

The "Maximum Bid Size" under chapter titles "Issue Structure" on page no. 290 of the Red Herring Prospectus shall stand replaced with below mentioned:

ISSUE STRUCTURE

Particulars	QIBs	Non - Institutional Bidders	Individual Investors/Bidders (who applies for minimum application size)
Minimum Bid Size	Such number of Equity Shares and in multiples of [●] Equity Shares that the Bid Amount exceeds ₹ 200,000 for more than two lots.	Such number of Equity shares in multiple of [●] Equity shares such that the application is for more than two lots.	[●] Equity Shares in multiple of [●] Equity shares such that Bid Amount exceeds ₹ 200,000 and shall be two lots per application.
Maximum Bid Size	Such number of Equity Shares in multiples of [●] Equity Shares not exceeding the size of the Net Issue (excluding the Anchor portion), subject to applicable limits.	Such number of Equity Shares in multiples of [●] Equity Shares not exceeding the size of the Net Issue (excluding the QIB portion), subject to limits as applicable to the Bidder.	For Individuals Investors: Such number of Equity Shares in multiples of [●] Equity Shares such that the application size doesn't exceed 2 lots.

Accordingly, the any material communication and advertisements issued by or on behalf of the Company in relation to the Issue shall stand amended to the extent of and should be read with the above.

Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Red Herring Prospectus dated September 16, 2025 ("Red Herring Prospectus") filed with Registrar of Companies, Pune.

BOOK RUNNING LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 SMART HORIZON CAPITAL ADVISORS PRIVATE LIMITED (Formerly Known as Shreni Capital Advisors Private Limited) Address: B/908, Western Edge II, Kanakia Space, Behind Metro Mall, off Western Express Highway, Magathane, Borivali East, Mumbai - 400066, Maharashtra, India. Telephone: 022-28706822 E-mail: director@shcapl.com Investors Grievance e-mail: investor@shcapl.com Contact Person: Mr. Parth Shah Website: www.shcapl.com SEBI Registration Number: INM000013183	 BIGSHARE SERVICES PRIVATE LIMITED Address: Office No. S6-2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East), Mumbai - 400 093, Maharashtra, India Telephone: 022 - 6263 8200 E-mail: ipo@bigshareonline.com Investor Grievance E-mail: investor@bigshareonline.com Website: www.bigshareonline.com Contact Person: Mr. Asif Sayyed SEBI Registration Number: INR000001385	 Ms. Barkha Mohit Bharuka Company Secretary and Compliance Officer. Address: Unit No. 502A, 5th floor, Om Chambers, Plot No. T-29, 30, 31, T Block, Bhosari I.E., Pune, Pune City, Maharashtra, India- 411026 Telephone: +91 7757950799 Email: compliance@telgeprojects.com Website: https://telgeprojects.com/ Investors can contact the Company Secretary and Compliance Officer or the Registrar to the issue in case of any pre-issue or post-issue related grievances, grievances including non-receipt of letters of allotment, non-credit of allotted equity shares in the respective beneficiary account, non-receipt of refund orders or non-receipt of funds by electronic mode, etc. For all issue related queries and for redressal of complaints, investors may also write to the BRLMs.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Red Herring Prospectus.

For TELGE PROJECTS LIMITED

Sd/-

Ms. Shraddha Shailesh Telge

Chairman, Managing Director cum Chief Executive Officer

DIN: 08052730

Telge Projects Limited is proposing, subject to market conditions and other considerations, public issue of its Equity Shares and has filed the Red Herring Prospectus with the Registrar of Companies, Pune on September 16, 2025. The Red Herring Prospectus is available on the website of the Book Running Lead Manager at www.shcapl.com, the website of the BSE i.e., www.bseindia.com, and website of our Company at <https://telgeprojects.com/>.

Investor should note that investment in equity shares involves a high degree of risk. For details, investors should refer to and rely on the Red Herring Prospectus, including the section titled "Risk Factors" of the Red Herring Prospectus, which has been filed with ROC. The Equity Shares have not been and will not be registered under the U.S. Securities Act ("the Securities Act") or any state securities laws in United States and may not be issued or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulations under the securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act of 1933.

AdBaa2

IndoStar Capital Finance Limited

Registered Office: Silver Utopia, Third Floor, Unit No 301-A,
Opposite P & G Plaza, Cardinal Graciosa Road, Chakala, Andheri (E), Mumbai - 400099.
Website: <https://www.indostarcapital.com/>

INVITATION FOR COUNTER BIDS FOR SALE OF STRESSED ASSETS OF INDOSTAR CAPITAL FINANCE LIMITED

IndoStar Capital Finance Limited (ICFL), intends to sell certain stressed assets, the details of which are more particularly set out below and the Public Notice referred to below (**Proposed Sale**). ICFL now invites counter bids (**Counter Bids**) from ARCs for the sale of certain stressed assets on its books, as per the extant RBI guidelines (**Interested Parties**). Eligible Interested Parties may download the detailed public notice document dated September 24, 2025 from the website of ICFL <https://www.indostarcapital.com/> (**Public Notice**). The Proposed Sale shall be on an 'as is where is, as is what is, whatever there is and without recourse basis' and is being conducted under the Swiss Challenge Method, based on an existing offer received by ICFL (**Primary Offer**) at the price set out below (**Reserve Price/ Base Bid**). Please note that the Proposed Sale will be subject to the outcome of the Counter Bid process and final approval by the competent authority of ICFL.

Total outstanding as on 31st July, 2025	Reserve Price/ Base Bid	Terms of Proposed Sale
INR 309.62.12.983/- (Rupees Three Hundred Nine Crores Sixty Two Lakhs Twelve Thousand Nine Hundred Eighty-Three Only)	INR 220.30.00.000/- (Rupees Two Hundred Twenty Crores Thirty Lakhs Only)	As per the terms and conditions set out under the Public Notice.

KEI INDUSTRIES LIMITED
Wires & Cables
Regd. Office: D-90, Okhla Industrial Area, Phase I, New Delhi-110 020
Phone: 91-11-26818646/26818642 | Website: www.kei-ind.com
E-mail: kei@kei-ind.com
(CIN: L74890DL1992PLC051527)

NOTICE TO SHAREHOLDERS
Special Window for Re-lodgement of Transfer Requests of Physical Shares
This is to inform all concerned shareholders that, pursuant to SEBI Circular No. SEBI/HO/ MIRDSD-PoD/PI/CIR/2025/97 dated July 02, 2025, a special window for the re-lodgement of transfer deeds relating to physical securities has been opened for a period of six months, from **July 07, 2025, to January 06, 2026**.
This initiative is applicable to transfer requests that were originally submitted prior to **April 01, 2019**, but were either rejected, returned, or not processed due to deficiencies in documentation or other procedural issues.
This facility also extends to shareholders who were eligible but missed the earlier deadline of **March 31, 2021**, for re-lodgement under the previous SEBI framework. Such shareholders may now re-submit their transfer requests during this newly announced window.
Please note that all re-lodged transfer requests will be processed strictly in dematerialized form. Concerned shareholders are advised to take note of this opportunity and re-lodge their transfer requests along with the requisite documents to the Company's Registrar and Share Transfer Agent, MAS Services Limited, at T-34, II Floor, Okhla Industrial Area, Phase-II, New Delhi - 110020. Contact No.: +91 11 2638 7261, 82, 83; Email: investor@masserv.com.
For KEI Industries Limited
Sd/-
Kishore Kunal
Sr. VP (Corporate Finance) and Company Secretary

Place of Signing: New Delhi
Date: 23.09.2025

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES OR UNITS NOR IS IT A PROSPECTUS ANNOUNCEMENT. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA. INITIAL PUBLIC OFFERING OF EQUITY SHARES ON THE MAIN BOARD OF THE BSE LIMITED ("BSE") AND "NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE", AND TOGETHER WITH BSE, THE "STOCK EXCHANGES") IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS")

PUBLIC ANNOUNCEMENT



(Please scan this QR code to view the Draft Red Herring Prospectus)



MEDICAP HEALTHCARE LIMITED

Our Company was originally formed as a partnership firm under the Indian Partnership Act, 1932 in the name and style of "Medicap INC" pursuant to a partnership deed dated April 01, 2014, with Kamal Aggarwal and Rajveer Aggarwal as its partners. Subsequently, by way of an indenture of partnership dated April 15, 2017, Rajesh C. Gandhi, Minal Kamal Aggarwal, Swati Vihang Bakshi, Himanshu Prafulchandra Purohit and Kanishka Kamal Aggarwal, joined Medicap INC as partners. In accordance with the provisions of Part I, Chapter XXI, Section 336 of the Companies Act, 2013, the partnership firm was converted to a public limited company under the name and style of "Medicap Healthcare Limited", and a fresh certificate of incorporation dated June 02, 2017 was issued by the RoC. For further details relating to the changes in the name and registered office of our Company, see "History and Certain Corporate Matters" on page 212 of the draft red herring prospectus dated September 22, 2025 ("DRHP").

Registered Office: E-73, GIDC Manjarur, Vadodara, Gujarat - 391775, India.

Contact Person: Leena Kumari Jain, Company Secretary and Compliance Officer | **Telephone:** +91 97734 72846;

E-mail: investor.relations@medicapinc.com; **Website:** <https://medicaphealthcare.in/>; **Corporate Identity Number:** U33309GJ20017PLC097697

OUR PROMOTERS: KAMALKUMAR AGGARWAL, RAJVEER KAMAL AGGARWAL AND MINAL AGGARWAL

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH ("EQUITY SHARES") OF MEDICAP HEALTHCARE LIMITED ("COMPANY" OR "ISSUER") FOR CASH AT A PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [●] PER EQUITY SHARE) ("ISSUE PRICE") AGGREGATING UP TO ₹ 2,400 MILLION ("THE ISSUE") THE ISSUE SHALL CONSTITUTE [●] % OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGER, MAY CONSIDER A PRE-IPO PLACEMENT AGGREGATING UP TO ₹ 480.00 MILLION, PRIOR TO FILING OF THE RED HERRING PROSPECTUS WITH THE ROC. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGER. IF THE PRE-IPO PLACEMENT IS COMPLETED, THE AMOUNT RAISED PURSUANT TO THE PRE-IPO PLACEMENT WILL BE REDUCED FROM THE ISSUE, SUBJECT TO COMPLIANCE WITH RULE 19(2)(B) OF THE SCRR. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, SHALL NOT EXCEED 20% OF THE SIZE OF THE ISSUE. PRIOR TO THE COMPLETION OF THE ISSUE AND ALLOTMENT PURSUANT TO THE PRE-IPO PLACEMENT, OUR COMPANY SHALL APPROPRIATELY INTIMATE THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT, THAT THERE IS NO GUARANTEE THAT OUR COMPANY MAY PROCEED WITH THE ISSUE OR THE ISSUE MAY BE SUCCESSFUL AND WILL RESULT IN LISTING OF THE EQUITY SHARES ON THE STOCK EXCHANGES. FURTHER, RELEVANT DISCLOSURES IN RELATION TO SUCH INTIMATION TO THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT (IF UNDERTAKEN) SHALL BE APPROPRIATELY MADE IN THE RELEVANT SECTIONS OF THE RED HERRING PROSPECTUS AND PROSPECTUS, THE PRICE BAND, THE MINIMUM BID LOT, IF ANY, WILL BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLM, AND WILL BE ADVERTISED IN ALL EDITIONS OF [●], AN ENGLISH NATIONAL DAILY NEWSPAPER, ALL EDITIONS OF [●], A HINDI NATIONAL DAILY NEWSPAPER AND [●] EDITIONS OF [●], A GUJARATI DAILY NEWSPAPER (GUJARATI BEING THE REGIONAL LANGUAGE OF GUJARAT, WHERE OUR REGISTERED OFFICE IS LOCATED), EACH WITH WIDE CIRCULATION, AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE STOCK EXCHANGES FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITES IN ACCORDANCE WITH THE SEBI ICDR REGULATIONS.

In case of any revision in the Price Band, the Bid/Issue Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company, in consultation of the BRLM, for reasons to be recorded in writing, may extend the Bid/Issue Period for a minimum of one Working Day, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the Book Running Lead Manager and at the terminals of the Members of the Syndicate and by intimation to Self-Certified Syndicate Banks ("SCSBs"), other Designated Intermediaries and the Sponsor Bank(s), as applicable.

This Issue is being made in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations. The Issue is being made through the Book Building Process and is in compliance with Regulation 6(1) of the SEBI ICDR Regulations wherein in terms of Regulation 32(1) of the SEBI ICDR Regulations, not more than 50% of the Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs"), and such portion, the "QIB Portion" provided that our Company, in consultation with the BRLM, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which at least one-third shall be available for allocation to domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Issue shall be available for allocation to Non-Institutional Bidders out of which (a) one-third of such portion shall be reserved for applicants with application size of more than ₹ 20 million and up to ₹ 1.00 million; and (b) two-third of such portion shall be reserved for applicants with application size of more than ₹ 1.00 million, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders and not less than 35% of the Issue shall be available for allocation to Retail Individual Bidders ("RIBs") in accordance with the SEBI ICDR Regulations ("Retail Portion"), subject to valid Bids being received from them at or above the Issue Price. Further all potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective bank accounts (including UPI ID for UPI Bidders using UPI Mechanism) (as defined hereinafter) in which the Bid amount will be blocked by the SCSBs or the Sponsor Banks, as applicable, to participate in the Issue. Anchor Investors are not permitted to participate in the Anchor Investor Portion of the Issue through the ASBA process. For details, see "Issue Procedure" on page 379 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares pursuant to the Issue and has filed the DRHP dated September 22, 2025, with the Securities and Exchange Board of India ("SEBI") and with the Stock Exchanges. Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI and the Stock Exchanges has been made public for comments, if any, for a period of at least 21 days from the date of such filing by hosting it on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges at www.bseindia.com and www.nseindia.com, on the website of the Company at <https://medicaphealthcare.in/>; and on the website of the Book Running Lead Manager ("BRLM"), i.e. Aryaman Financial Services Limited at www.afsl.co.in, respectively. Our Company invites the public to give their comments on the DRHP filed with SEBI and the Stock Exchanges, with respect to disclosures made in the DRHP. The members of the public are requested to send a copy of the comments to SEBI, to the Company Secretary and Compliance Officer of our Company and/or the BRLM at their respective addresses mentioned herein. All comments must be received by SEBI and/or our Company and/or the Company Secretary and Compliance Officer of our Company and/or the BRLM in relation to the Issue on or before 5.00 p.m. on the 21st day from the aforesaid date of filing of the DRHP with SEBI.

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they are taking to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors shall rely on their own examination of our Company and the Issue, including the risks involved. The Equity Shares in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of this Draft Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 33 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be taken after a Red Herring Prospectus ("RHP") has been filed with the RoC and must be made solely on the basis of such RHP as there may be material changes in RHP from DRHP. The Equity Shares, when offered through the RHP, are proposed to be listed on the Stock Exchanges.

For details of the share capital and capital structure and the names of the signatories to the memorandum and the number of shares subscribed by them of our Company, please see the section titled "Capital Structure" on page 77 of the DRHP. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in the Memorandum of Association, please see the section titled "History and Certain Corporate Matters - Brief history of our Company" on page 212 of the DRHP.

DETAILS OF THE BOOK RUNNING LEAD MANAGER	REGISTRAR TO THE ISSUE
 Aryaman Financial Services Limited 60, Khatau Building, Gr. Floor, Alkesh Dinesh Modi Marg, Fort, Mumbai - 400 001, Maharashtra, India Telephone: +91-22-6216 6999 E-mail: ipo@afsl.co.in Investor Grievance E-mail: feedback@afsl.co.in Website: www.afsl.co.in Contact Person: Vatsal Ganatra/ Rocky Shyamal SEBI Registration Number: INM000011344	 Name: KFIN Technologies Limited Address: Selenium Tower-B, Plot 31 & 32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad, 500 032, Telangana Telephone: +91 40 6716 2222 E-mail: medicap.ipo@kfintech.com Investor Grievance E-mail: einward.ris@kfintech.com Website: www.kfintech.com Contact Person: M Murali Krishna SEBI Registration Number: INR000000221

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For MEDICAP HEALTHCARE LIMITED
On behalf of the Board of Directors

Sd/-

Leena Kumari Jain

Company Secretary and Compliance Officer

MEDICAP HEALTHCARE LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP with SEBI and the Stock Exchanges on September 22, 2025. The DRHP is available on the website of SEBI at www.sebi.gov.in, as well as on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at <https://medicaphealthcare.in/>; and on the website of the Book Running Lead Manager ("BRLM"), i.e. Aryaman Financial Services Limited at www.afsl.co.in, respectively. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" beginning on page 33 of the DRHP filed with SEBI and the Stock Exchanges. Potential Bidders should not rely on the DRHP filed with SEBI and the Stock Exchanges for making any investment decision and should instead rely on the RHP, when filed, for making investment decision.

The Equity Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or the securities laws of any state of the United States and, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. The Equity Shares offered in the Issue are being offered and sold only outside the United States in "offshore transactions" as defined in and in reliance on Regulation S under the U.S. Securities Act ("Regulation S"). There will be no public offering in the United States.

Adfactors 452/25

